Loading
Built the melanoma and immunotherapy institute at Sheba that has been growing patients' own tumour-infiltrating lymphocytes and giving them back since 2006, more than a decade before any regulator approved the idea.
Jacob Schachter directs the Ella Lemelbaum Institute for Immuno-Oncology and Melanoma at Sheba Medical Center, one of very few centres outside the United States to run a tumour-infiltrating lymphocyte programme at scale and for long enough to report durable outcomes. The institute's intent-to-treat analysis, published in Clinical Cancer Research with Michal Besser as first author, enrolled 80 patients with stage IV melanoma and treated 57 with unselected or "young" TIL and high-dose interleukin-2 after non-myeloablative lymphodepletion. The overall response rate was 29 percent for all enrolled patients and 40 percent for those treated, with five complete and 18 partial remissions; all complete responders remained in unmaintained remission at a median 28 months and three-year survival among responders was 78 percent. Twenty-three patients could not be treated, mostly because they deteriorated while the cells were being grown, which is the honest cost of a three-week manufacturing step. Schachter has also been an investigator on the pivotal pembrolizumab melanoma trials.
Shares Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies, Tel Aviv University, Sheba Medical Center, TIL therapy and the tags clinician-scientist, immunotherapy.
Shares Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies, Tel Aviv University, Sheba Medical Center, TIL therapy.
Shares Melanoma and the tags clinician-scientist, immunotherapy.
Shares Tel Aviv University, Sheba Medical Center and the tag clinician-scientist.
Shares the tags clinician-scientist, immunotherapy.
Shares the tags clinician-scientist, immunotherapy.
Shares the tags clinician-scientist, immunotherapy.
Shares the tags clinician-scientist, immunotherapy.